(Reuters) – Regeneron Pharmaceuticals said on Wednesday its investigational gene therapy improved hearing to normal levels in a child within 24 weeks in an early to mid-stage study.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Shounak Dasgupta)
Brought to you by www.srnnews.com
